Cullen/Frost Bankers’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.09M | Buy |
18,291
+1,723
| +10% | +$764K | 0.09% | 184 |
|
|
2026
Q1 | $7.4M | Buy |
16,568
+15,978
| +2,708% | +$7.45M | 0.08% | 185 |
|
|
2025
Q4 | $267K | Buy |
590
+85
| +17% | +$36.6K | ﹤0.01% | 518 |
|
|
2025
Q3 | $198K | Sell |
505
-177
| -26% | -$74K | ﹤0.01% | 535 |
|
|
2025
Q2 | $304K | Sell |
682
-345
| -34% | -$159K | ﹤0.01% | 472 |
|
|
2025
Q1 | $498K | Buy |
1,027
+134
| +15% | +$62.4K | 0.01% | 392 |
|
|
2024
Q4 | $360K | Buy |
893
+20
| +2% | +$9.27K | ﹤0.01% | 422 |
|
|
2024
Q3 | $406K | Sell |
873
-106
| -11% | -$50.9K | 0.01% | 418 |
|
|
2024
Q2 | $459K | Buy |
979
+149
| +18% | +$64.7K | 0.01% | 391 |
|
|
2024
Q1 | $347K | Sell |
830
-43
| -5% | -$18.2K | 0.01% | 411 |
|
|
2023
Q4 | $355K | Sell |
873
-551
| -39% | -$204K | 0.01% | 409 |
|
|
2023
Q3 | $495K | Sell |
1,424
-182
| -11% | -$63.7K | 0.01% | 381 |
|
|
2023
Q2 | $565K | Sell |
1,606
-224
| -12% | -$75.5K | 0.01% | 364 |
|
|
2023
Q1 | $577K | Buy |
1,830
+90
| +5% | +$27K | 0.01% | 365 |
|
|
2022
Q4 | $502K | Sell |
1,740
-401
| -19% | -$122K | 0.01% | 386 |
|
|
2022
Q3 | $620K | Sell |
2,141
-378
| -15% | -$109K | 0.01% | 347 |
|
|
2022
Q2 | $710K | Sell |
2,519
-123
| -5% | -$32.9K | 0.02% | 337 |
|
|
2022
Q1 | $689K | Sell |
2,642
-286
| -10% | -$67.9K | 0.01% | 352 |
|
|
2021
Q4 | $643K | Sell |
2,928
-1,039
| -26% | -$202K | 0.01% | 365 |
|
|
2021
Q3 | $720K | Sell |
3,967
-67,855
| -94% | -$13.2M | 0.01% | 345 |
|
|
2021
Q2 | $14.5M | Buy |
71,822
+56
| +0.1% | +$11.7K | 0.29% | 88 |
|
|
2021
Q1 | $15.4M | Sell |
71,766
-8,253
| -10% | -$1.81M | 0.34% | 81 |
|
|
2020
Q4 | $18.9M | Sell |
80,019
-414
| -0.5% | -$95K | 0.44% | 63 |
|
|
2020
Q3 | $21.9M | Buy |
80,433
+778
| +1% | +$215K | 0.55% | 48 |
|
|
2020
Q2 | $23.1M | Buy |
79,655
+2,830
| +4% | +$767K | 0.61% | 39 |
|
|
2020
Q1 | $18.3M | Buy |
76,825
+7,795
| +11% | +$1.79M | 0.64% | 44 |
|
|
2019
Q4 | $15.1M | Buy |
69,030
+4,446
| +7% | +$900K | 0.41% | 75 |
|
|
2019
Q3 | $10.9M | Buy |
64,584
+14,021
| +28% | +$2.48M | 0.32% | 95 |
|
|
2019
Q2 | $9.27M | Sell |
50,563
-1,185
| -2% | -$207K | 0.29% | 104 |
|
|
2019
Q1 | $9.51M | Buy |
51,748
+7,308
| +16% | +$1.35M | 0.29% | 107 |
|
|
2018
Q4 | $7.37M | Buy |
44,440
+42,651
| +2,384% | +$7.39M | 0.27% | 115 |
|
|
2018
Q3 | $345K | Sell |
1,789
-537
| -23% | -$95.6K | 0.01% | 333 |
|
|
2018
Q2 | $395K | Hold |
2,326
| – | – | 0.01% | 319 |
|
|
2018
Q1 | $379K | Sell |
2,326
-48
| -2% | -$7.84K | 0.01% | 321 |
|
|
2017
Q4 | $356K | Buy |
2,374
+27
| +1% | +$4K | 0.01% | 311 |
|
|
2017
Q3 | $357K | Buy |
2,347
+297
| +14% | +$44.7K | 0.01% | 312 |
|
|
2017
Q2 | $264K | Sell |
2,050
-30
| -1% | -$3.61K | 0.01% | 332 |
|
|
2017
Q1 | $228K | Buy |
+2,080
| New | +$183K | 0.01% | 347 |
|
|
2016
Q1 | – | Sell |
-1,758
| Closed | -$221K | – | 380 |
|
|
2015
Q4 | $221K | Buy |
+1,758
| New | +$212K | 0.01% | 356 |
|
|
2015
Q3 | – | Sell |
-3,435
| Closed | -$424K | – | 388 |
|
|
2015
Q2 | $424K | Buy |
3,435
+90
| +3% | +$11.3K | 0.02% | 305 |
|
|
2015
Q1 | $395K | Buy |
3,345
+29
| +0.9% | +$3.48K | 0.01% | 315 |
|
|
2014
Q4 | $394K | Hold |
3,316
| – | – | 0.02% | 321 |
|
|
2014
Q3 | $372K | Hold |
3,316
| – | – | 0.02% | 316 |
|
|
2014
Q2 | $314K | Buy |
+3,316
| New | +$233K | 0.01% | 329 |
|
|
2014
Q1 | – | Sell |
-80,903
| Closed | -$6.01M | – | 391 |
|
|
2013
Q4 | $6.01M | Sell |
80,903
-11,321
| -12% | -$788K | 0.27% | 115 |
|
|
2013
Q3 | $6.99M | Buy |
92,224
+26,687
| +41% | +$2.12M | 0.34% | 100 |
|
|
2013
Q2 | $5.25M | Buy |
+65,537
| New | +$4.83M | 0.28% | 118 |
|
Other funds holding VRTX
Cullen/Frost Bankers's VRTX Position: Q2 2026 in Review
Cullen/Frost Bankers increased its Vertex Pharmaceuticals (VRTX) stake by 10% in Q2 2026, buying an estimated $764K and bringing the position to 18,291 shares worth $9.09M. The position accounts for 0.09% of the portfolio, ranked #184.
Cullen/Frost Bankers first reported a position in VRTX in Q2 2013 and has held it in 47 quarters since. The position peaked at $23.1M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cullen/Frost Bankers held 18,291 shares of Vertex Pharmaceuticals worth $9.09M as of Q2 2026.
- Cullen/Frost Bankers bought 1,723 Vertex Pharmaceuticals shares in Q2 2026, an estimated $764K.
- Vertex Pharmaceuticals made up 0.09% of Cullen/Frost Bankers's portfolio in Q2 2026, its #184 holding.
- Cullen/Frost Bankers first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 47 quarters since.
- Cullen/Frost Bankers's Vertex Pharmaceuticals position peaked at $23.1M in Q2 2020.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.